Logo image of ALESE.PA

ENTECH SACA (ALESE.PA) Stock Fundamental Analysis

EPA:ALESE - Euronext Paris - Matif - FR0014004362 - Common Stock - Currency: EUR

7.6  -0.02 (-0.26%)

Fundamental Rating

4

Overall ALESE gets a fundamental rating of 4 out of 10. We evaluated ALESE against 43 industry peers in the Construction & Engineering industry. The financial health of ALESE is average, but there are quite some concerns on its profitability. ALESE is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ALESE had negative earnings in the past year.
ALESE had a negative operating cash flow in the past year.
In the past 5 years ALESE reported 4 times negative net income.
In the past 5 years ALESE always reported negative operating cash flow.
ALESE.PA Yearly Net Income VS EBIT VS OCF VS FCFALESE.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 0 -2M -4M -6M -8M -10M

1.2 Ratios

ALESE has a worse Return On Assets (-1.53%) than 83.72% of its industry peers.
With a Return On Equity value of -3.00%, ALESE is not doing good in the industry: 81.40% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -1.53%
ROE -3%
ROIC N/A
ROA(3y)-2.33%
ROA(5y)-0.87%
ROE(3y)-4.85%
ROE(5y)-2.97%
ROIC(3y)N/A
ROIC(5y)N/A
ALESE.PA Yearly ROA, ROE, ROICALESE.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 10 -10

1.3 Margins

With a decent Gross Margin value of 48.83%, ALESE is doing good in the industry, outperforming 67.44% of the companies in the same industry.
ALESE's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for ALESE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 48.83%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.07%
GM growth 5YN/A
ALESE.PA Yearly Profit, Operating, Gross MarginsALESE.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 20 40 60

More info and screens

5

2. Health

2.1 Basic Checks

ALESE does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ALESE has about the same amount of shares outstanding.
Compared to 1 year ago, ALESE has a worse debt to assets ratio.
ALESE.PA Yearly Shares OutstandingALESE.PA Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 5M 10M
ALESE.PA Yearly Total Debt VS Total AssetsALESE.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

An Altman-Z score of 4.19 indicates that ALESE is not in any danger for bankruptcy at the moment.
ALESE's Altman-Z score of 4.19 is amongst the best of the industry. ALESE outperforms 90.70% of its industry peers.
ALESE has a Debt/Equity ratio of 0.08. This is a healthy value indicating a solid balance between debt and equity.
With an excellent Debt to Equity ratio value of 0.08, ALESE belongs to the best of the industry, outperforming 90.70% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Altman-Z 4.19
ROIC/WACCN/A
WACC7.65%
ALESE.PA Yearly LT Debt VS Equity VS FCFALESE.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

A Current Ratio of 1.94 indicates that ALESE should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.94, ALESE belongs to the top of the industry, outperforming 81.40% of the companies in the same industry.
A Quick Ratio of 1.81 indicates that ALESE should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.81, ALESE belongs to the top of the industry, outperforming 86.05% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.94
Quick Ratio 1.81
ALESE.PA Yearly Current Assets VS Current LiabilitesALESE.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

7

3. Growth

3.1 Past

ALESE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 73.07%, which is quite impressive.
Looking at the last year, ALESE shows a very strong growth in Revenue. The Revenue has grown by 35.96%.
ALESE shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 68.95% yearly.
EPS 1Y (TTM)73.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.33%
Revenue 1Y (TTM)35.96%
Revenue growth 3Y68.95%
Revenue growth 5YN/A
Sales Q2Q%43.81%

3.2 Future

ALESE is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 116.80% yearly.
ALESE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 38.98% yearly.
EPS Next Y166.67%
EPS Next 2Y154.48%
EPS Next 3Y116.8%
EPS Next 5YN/A
Revenue Next Year42.47%
Revenue Next 2Y51.97%
Revenue Next 3Y32.1%
Revenue Next 5Y38.98%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ALESE.PA Yearly Revenue VS EstimatesALESE.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
ALESE.PA Yearly EPS VS EstimatesALESE.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0 0.2 0.4 0.6 0.8

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALESE. In the last year negative earnings were reported.
A Price/Forward Earnings ratio of 15.70 indicates a correct valuation of ALESE.
ALESE's Price/Forward Earnings ratio is a bit more expensive when compared to the industry. ALESE is more expensive than 62.79% of the companies in the same industry.
ALESE's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 20.42.
Industry RankSector Rank
PE N/A
Fwd PE 15.7
ALESE.PA Price Earnings VS Forward Price EarningsALESE.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -50 -100 -150

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, ALESE is valued expensively inside the industry as 81.40% of the companies are valued cheaper.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 232.44
ALESE.PA Per share dataALESE.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

ALESE's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ALESE's earnings are expected to grow with 116.80% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y154.48%
EPS Next 3Y116.8%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ALESE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ENTECH SACA

EPA:ALESE (5/8/2025, 7:00:00 PM)

7.6

-0.02 (-0.26%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryConstruction & Engineering
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners11.95%
Inst Owner ChangeN/A
Ins Owners63.72%
Ins Owner ChangeN/A
Market Cap111.57M
Analysts86
Price Target11.37 (49.61%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.9%
PT rev (3m)0.9%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-26.32%
EPS NY rev (3m)180%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)9.69%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 15.7
P/S 2.1
P/FCF N/A
P/OCF N/A
P/B 4.34
P/tB 5.63
EV/EBITDA 232.44
EPS(TTM)-0.05
EYN/A
EPS(NY)0.48
Fwd EY6.37%
FCF(TTM)-0.24
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS3.62
BVpS1.75
TBVpS1.35
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1.53%
ROE -3%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 48.83%
FCFM N/A
ROA(3y)-2.33%
ROA(5y)-0.87%
ROE(3y)-4.85%
ROE(5y)-2.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.07%
GM growth 5YN/A
F-Score5
Asset Turnover1.06
Health
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Debt/EBITDA 4.3
Cap/Depr 243.28%
Cap/Sales 6.22%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.94
Quick Ratio 1.81
Altman-Z 4.19
F-Score5
WACC7.65%
ROIC/WACCN/A
Cap/Depr(3y)285.26%
Cap/Depr(5y)212.15%
Cap/Sales(3y)7.1%
Cap/Sales(5y)9.44%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)73.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.33%
EPS Next Y166.67%
EPS Next 2Y154.48%
EPS Next 3Y116.8%
EPS Next 5YN/A
Revenue 1Y (TTM)35.96%
Revenue growth 3Y68.95%
Revenue growth 5YN/A
Sales Q2Q%43.81%
Revenue Next Year42.47%
Revenue Next 2Y51.97%
Revenue Next 3Y32.1%
Revenue Next 5Y38.98%
EBIT growth 1Y72.69%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year317.14%
EBIT Next 3Y118.68%
EBIT Next 5Y104.68%
FCF growth 1Y65.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y98.14%
OCF growth 3YN/A
OCF growth 5YN/A